Global Epilepsy Drugs Market 2016-2020

Description: About the Epilepsy Drugs Market

Epilepsy is characterized by recurrent seizures caused by the improper balance between inhibitory and excitatory signals in the brain. The symptoms of epilepsy, caused by brain malformations and tumors, birth trauma, and high-risk pregnancies, can be benign or life-threatening. A majority of epilepsy cases have an unknown etiology.

Etiology

Etiology varies according to the age of a person. Some individuals genetically inherit the disease while the cause of the disease in others is unknown. Head injuries, tumors, autism spectrum disorder, or stroke can also cause the disorder.

The analysts forecast the global epilepsy drugs market to grow at a CAGR of 4.45% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global epilepsy drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent epilepsy and related seizures. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

The report, Global Epilepsy Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Eisai
- GSK
- Pfizer
- UCB

Other prominent vendors
- AbbVie
- Acorda Therapeutics
- Alexza Pharmaceuticals
- Aprecia Pharmaceuticals
- Aurobindo Pharma
- Biscayne Pharmaceuticals
- CURx Pharmaceuticals
- Dainippon Sumitomo Pharma
- D-Pharm
- F. Hoffmann-La Roche
- Grupo Ferrer Internacional
- GW Pharmaceuticals
- Insero Health
- INSYS Therapeutics
- Janssen Pharmaceuticals
Market drivers
- Tentative approval of late-stage pipeline molecules

Market challenges
- Social stigma associated with epilepsy

Market trends
- Reformulation of marketed drugs

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Contents:
- PART 01: Executive summary
  - Highlights
- PART 02: Scope of the report
  - Market overview
  - Top-vendor offerings
- PART 03: Market research methodology
  - Research methodology
  - Economic indicators
- PART 04: Introduction
  - Key market highlights
  - Epilepsy: An overview
- PART 05: Pipeline analysis
- PART 06: Key buying criteria for anti-epileptic drugs
PART 07: Market landscape
- Market overview
- Five forces analysis

PART 08: Market segmentation by generation of drugs
- First-generation anti-epileptic drugs
- Second-generation anti-epileptic drugs
- Third-generation anti-epileptic drugs

PART 09: Market segmentation by spectrum of activity
- Narrow-spectrum anti-epileptic drugs
- Broad-spectrum anti-epileptic drugs

PART 10: Market segmentation by type of seizures
- Partial onset seizures
- Generalized seizures

PART 11: Geographical segmentation
- Global epilepsy drugs market by geography 2016-2020
- Epilepsy drugs market in Americas
- Epilepsy drugs market in US
- Epilepsy drugs market in EMEA
- Epilepsy drugs market in APAC
- Epilepsy drugs market in Japan
- Epilepsy drugs market in Australia
- Epilepsy drugs market in China
- Epilepsy drugs market in India

PART 12: Market drivers
- Tentative approval of late-stage pipeline molecules
- Special regulatory designations
- Development of novel therapeutics using innovative technologies

PART 13: Impact of drivers

PART 14: Market challenges
- Social stigma associated with epilepsy
- Growing use of seizure management devices is a threat to drug therapies
- Gradual decrease in incentives/investment by vendors for new drug development

PART 15: Impact of drivers and challenges

PART 16: Market trends
- Development of devices and smartphone apps to detect seizures and track medications
- Reformulation of marketed drugs
- Increased uptake of new-generation drugs

PART 17: Vendor landscape
- Competitive scenario
- Key news

PART 18: Key vendor analysis
- Eisai
- GSK
- Pfizer
- UCB
- Other prominent vendors

PART 19: Appendix
- List of abbreviations

PART 20: About the Author
List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Pipeline portfolio: Epilepsy drugs
Exhibit 03: Percentage share of pipeline molecules for global epilepsy drugs market
Exhibit 04: Key buying criteria for anti-epileptic drugs
Exhibit 05: Global epilepsy drugs market snapshot: Developed and emerging markets 2015
Exhibit 06: Global epilepsy drugs market 2015-2020 ($ billions)
Exhibit 07: A few research studies targeting cause of epilepsy
Exhibit 08: Key buying criteria for anti-epileptic drugs
Exhibit 09: Five forces analysis
Exhibit 10: Timeline of development of anti-epileptic drugs
Exhibit 11: Segmentation of global anti-epileptic drugs market based on generation of drugs 2015
Exhibit 12: Opportunity analysis of global epilepsy drugs market by generation of drugs
Exhibit 13: Segmentation of global epilepsy drugs market by the spectrum of activity of drugs 2015
Exhibit 14: Segmentation of global epilepsy drugs market based on type of seizures
Exhibit 15: Global epilepsy drugs market by geography 2015-2020
Exhibit 16: Global epilepsy drugs market by geography 2015 and 2020
Exhibit 17: Global epilepsy drugs market by geography 2015-2020 ($ billions)
Exhibit 18: Epilepsy drugs market in America 2015-2020 ($ billions)
Exhibit 19: Epilepsy drugs market in Americas by geography 2015
Exhibit 20: Comparison of US healthcare system: Before and after reforms
Exhibit 21: Epilepsy drugs market in US 2015-2020 ($ billions)
Exhibit 22: Epilepsy drugs market in EMEA by geography 2015
Exhibit 23: Epilepsy drugs market in EMEA 2015-2020 ($ billions)
Exhibit 24: Epilepsy drugs market in APAC 2015-2020 ($ billions)
Exhibit 25: Epilepsy drugs market in APAC by geography 2015
Exhibit 26: Epilepsy drugs market in Japan 2015-2020 ($ millions)
Exhibit 27: Epilepsy drugs market in Australia 2015-2020 ($ millions)
Exhibit 28: Epilepsy drugs market in China 2015-2020 ($ millions)
Exhibit 29: Epilepsy drugs market in India 2015-2020 ($ millions)
Exhibit 30: Impact of drivers
Exhibit 31: Impact of drivers and challenges
Exhibit 32: Position of key vendors in global epilepsy drugs market 2015
Exhibit 33: Geographical presence of key vendors
Exhibit 34: Company portfolio analysis in global epilepsy drugs market 2016-2020
Exhibit 35: Eisai: YoY revenue and growth rate of Fycompa (Americas and EMEA) 2013-2015 ($ millions)
Exhibit 36: Eisai: YoY revenue and growth rate of Zonegran (EMEA) 2013-2015 ($ millions)
Exhibit 37: Eisai: YoY revenue and growth rate of Banzel (Americas and EMEA) 2013-2015 ($ millions)
Exhibit 38: Eisai: YoY revenue and growth rate of Zebinix (EMEA) 2013-2015 ($ millions)
Exhibit 39: Eisai: Metrics analysis
Exhibit 40: GSK: YoY revenue and growth rate of Lamictal 2013-2015 ($ millions)
Exhibit 41: GSK: Metrics analysis
Exhibit 42: Pfizer: YoY revenue and growth rate of Lyrica 2013-2015 ($ billions)
Exhibit 43: Pfizer: YoY revenue and growth rate of Lyrica 2013-2015 ($ billions)
Exhibit 44: Pfizer: Metrics analysis
Exhibit 45: UCB: YoY revenue and growth rate of Keppra 2013-2015 ($ millions)
Exhibit 46: UCB: Geographical segmentation of Keppra by revenue 2015
Exhibit 47: UCB: YoY revenue and growth rate of Vimpat 2013-2015 ($ millions)
Exhibit 48: UCB: Geographical segmentation of Keppra by revenue 2015
Exhibit 49: UCB: Metrics analysis

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3776385/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- **Product Name:** Global Epilepsy Drugs Market 2016-2020
- **Web Address:** [http://www.researchandmarkets.com/reports/3776385/](http://www.researchandmarkets.com/reports/3776385/)
- **Office Code:** SCH3K9IO

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2500</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users</td>
<td></td>
<td>USD 3000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 10000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

- **Title:** Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
- **First Name:**
- **Last Name:**
- **Email Address:** *
- **Job Title:**
- **Organisation:**
- **Address:**
- **City:**
- **Postal / Zip Code:**
- **Country:**
- **Phone Number:**
- **Fax Number:**

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World